Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to “Hold” at Zacks Research

Zacks Research upgraded shares of Sarepta Therapeutics (NASDAQ:SRPT) from a strong sell rating to a hold rating in a research note issued to investors on Wednesday,Zacks.com reports.

Several other research firms also recently weighed in on SRPT. Piper Sandler dropped their target price on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating for the company in a research report on Thursday, July 9th. Wolfe Research raised shares of Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a research report on Thursday, July 9th. Wall Street Zen downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. HC Wainwright reissued a “buy” rating on shares of Sarepta Therapeutics in a report on Tuesday, July 28th. Finally, Weiss Ratings cut Sarepta Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, August 5th. Nine research analysts have rated the stock with a Buy rating, six have issued a Hold rating and five have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $25.06.

Sarepta Therapeutics Stock Up 0.2%

Shares of NASDAQ:SRPT opened at $18.42 on Wednesday. The company has a current ratio of 4.42, a quick ratio of 2.62 and a debt-to-equity ratio of 0.55. The company has a fifty day simple moving average of $17.03 and a 200 day simple moving average of $18.40. The firm has a market cap of $1.95 billion, a PE ratio of -6.35, a price-to-earnings-growth ratio of 0.24 and a beta of 0.23. Sarepta Therapeutics has a 12-month low of $14.68 and a 12-month high of $25.32.

Hedge Funds Weigh In On Sarepta Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Kestra Advisory Services LLC bought a new position in shares of Sarepta Therapeutics during the fourth quarter worth about $25,000. iSAM Funds UK Ltd bought a new stake in Sarepta Therapeutics in the 3rd quarter valued at about $25,000. Meeder Asset Management Inc. bought a new stake in Sarepta Therapeutics in the 2nd quarter valued at about $27,000. Ancora Advisors LLC lifted its position in Sarepta Therapeutics by 200.0% in the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Allworth Financial LP boosted its stake in Sarepta Therapeutics by 2,098.8% during the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 1,721 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.